An empirical analysis of overall survival in drug approvals by the US FDA (2006–2023)
Abstract Background The US Food and Drug Administration (FDA) has expanded the use of surrogate markers in drugs approved for oncology/hematology indications. This has likely resulted in a greater number of approvals and possibly drugs coming to market faster, but it is unknown whether these drugs a...
-д хадгалсан:
| Үндсэн зохиолчид: | , , |
|---|---|
| Формат: | Artigo |
| Хэл сонгох: | Inglês |
| Хэвлэсэн: |
Wiley
2024-04-01
|
| Цуврал: | Cancer Medicine |
| Нөхцлүүд: | |
| Онлайн хандалт: | https://doi.org/10.1002/cam4.7190 |
| Шошгууд: |
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|